Chromadex Corp (CDXC.OQ)
CDXC.OQ on NASDAQ Stock Exchange Capital Market
4.15USD
20 Apr 2018
4.15USD
20 Apr 2018
Change (% chg)
$-0.07 (-1.66%)
$-0.07 (-1.66%)
Prev Close
$4.22
$4.22
Open
$4.17
$4.17
Day's High
$4.22
$4.22
Day's Low
$4.13
$4.13
Volume
24,767
24,767
Avg. Vol
104,109
104,109
52-wk High
$7.24
$7.24
52-wk Low
$2.26
$2.26
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Buy | -0.05 | December | 23 Apr 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 1 | 1 | 1 | 1 |
| (2) OUTPERFORM | 1 | 1 | 1 | 1 |
| (3) HOLD | 0 | 0 | 0 | 0 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 1.50 | 1.50 | 1.50 | 1.50 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 2 | 8.19 | 8.38 | 8.00 | -- |
| Quarter Ending Sep-18 | 2 | 9.77 | 10.50 | 9.05 | -- |
| Year Ending Dec-18 | 2 | 35.83 | 37.00 | 34.66 | 85.00 |
| Year Ending Dec-19 | 2 | 57.37 | 66.00 | 48.74 | -- |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 2 | -0.05 | -0.03 | -0.06 | -- |
| Quarter Ending Sep-18 | 2 | -0.04 | -0.02 | -0.06 | -- |
| Year Ending Dec-18 | 2 | -0.17 | -0.10 | -0.23 | 0.36 |
| Year Ending Dec-19 | 2 | 0.00 | 0.12 | -0.12 | -- |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Dec-17 | 7.49 | 7.53 | 0.04 | 0.48 |
| Quarter Ending Sep-17 | 5.01 | 6.08 | 1.07 | 21.45 |
| Quarter Ending Jun-17 | 11.00 | 5.31 | 5.69 | 51.75 |
| Quarter Ending Mar-17 | 8.00 | 4.45 | 3.55 | 44.39 |
| Quarter Ending Dec-16 | 5.60 | 5.64 | 0.04 | 0.75 |
| Earnings (per share) | ||||
| Quarter Ending Dec-17 | -0.17 | -0.17 | 0.00 | -0.00 |
| Quarter Ending Sep-17 | -0.05 | -0.07 | 0.02 | -40.00 |
| Quarter Ending Jun-17 | 0.04 | -0.05 | 0.09 | 225.00 |
| Quarter Ending Mar-17 | 0.01 | -0.04 | 0.05 | 500.00 |
| Quarter Ending Dec-16 | -0.01 | -0.05 | 0.04 | -400.00 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 8.19 | 8.19 | 8.19 | 12.72 | -- |
| Quarter Ending Sep-18 | 9.77 | 9.77 | 9.77 | 15.27 | -- |
| Year Ending Dec-18 | 35.83 | 35.83 | 35.83 | 55.44 | 85.00 |
| Year Ending Dec-19 | 57.37 | 57.37 | 57.37 | 52.10 | -- |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | -0.05 | -0.05 | -0.05 | 0.01 | -- |
| Quarter Ending Sep-18 | -0.04 | -0.04 | -0.04 | 0.02 | -- |
| Year Ending Dec-18 | -0.17 | -0.17 | -0.12 | 0.07 | 0.36 |
| Year Ending Dec-19 | 0.00 | 0.00 | 0.01 | 0.01 | -- |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Jun-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 0 | 0 | 0 |
| Earnings | ||||
| Quarter Ending Jun-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 0 | 1 |
| Year Ending Dec-19 | 0 | 0 | 0 | 1 |
Earnings vs. 
Estimates- BRIEF-Chromadex Corporation Q4 Loss Per Share $0.17
- BRIEF-Chromadex Chairman Stephen Allen Will Retire From The Board
- BRIEF-ChromaDex Corp Sees Q4 2017 Revenue About $7.5 Mln
- BRIEF-Chromadex - Patent Trial And Appeal Board Of U.S. Patent And Trademark Office Denied Elysium Health's Request To Invalidate U.S. Patent
- BRIEF-ChromaDex And Watsons Expand Partnership With Tru Niagen Retail Launch In Singapore